Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC lifted its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 11.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,883 shares of the biotechnology company’s stock after acquiring an additional 1,615 shares during the quarter. HighTower Advisors LLC owned 0.11% of Anika Therapeutics worth $387,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Stonepine Capital Management LLC grew its position in Anika Therapeutics by 14.5% during the third quarter. Stonepine Capital Management LLC now owns 189,308 shares of the biotechnology company’s stock worth $4,676,000 after buying an additional 23,911 shares during the period. FMR LLC grew its stake in Anika Therapeutics by 25.3% in the 3rd quarter. FMR LLC now owns 24,721 shares of the biotechnology company’s stock worth $611,000 after acquiring an additional 4,996 shares during the period. Segall Bryant & Hamill LLC lifted its position in Anika Therapeutics by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 108,799 shares of the biotechnology company’s stock worth $2,687,000 after buying an additional 1,794 shares during the period. Quest Partners LLC boosted its position in shares of Anika Therapeutics by 115.8% in the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock worth $171,000 after acquiring an additional 3,705 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new stake in shares of Anika Therapeutics during the 3rd quarter valued at $238,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Anika Therapeutics Price Performance

Shares of ANIK opened at $16.31 on Monday. Anika Therapeutics, Inc. has a 12-month low of $15.82 and a 12-month high of $29.11. The stock has a market capitalization of $238.88 million, a P/E ratio of -2.45 and a beta of 0.89. The firm’s 50 day moving average is $19.14 and its 200-day moving average is $23.47.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ANIK. StockNews.com downgraded shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Barrington Research decreased their price objective on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, November 1st.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.